TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active Multiple Myeloma Stage II or III Durie Salmon~* Measurable levels of myeloma paraprotein in serum (≥1.0g/dL) or urine (≥ 0.2g excreted in a 24-hour collection sample)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2~* Women of child bearing potential must agree to abstain for heterosexual intercourse or use 2 methods of contraception, one effective (for example hormonal or tubal ligation) and one barrier (for example latex condom, diaphragm)~* Males must agree to use barrier contraception (latex condoms) when engaging in reproductive activity~Exclusion Criteria:~* Pregnant or lactating females~* Peripheral neuropathy ≥ to grade 2 of the NCI CTC.~* Prior history of malignancy unless subject has been free of disease for ≥ 3 years~* Lab abnormality: Absolute neutrophil count (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L)~* Lab abnormality: Platelet count \<50,000/mm\^3 (50.0 x 10\^9/L)~* Lab abnormality: Serum creatinine \>3.0 mg/dL (265 µmol/L)~* Lab abnormality: Serum glutamic oxaloacetic transaminase (SGOT) /Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase (SGPT)/Alanine transaminase (ALT) \>3.0 x upper limit of normal (ULN)~* Lab abnormality: Serum total bilirubin \> 2.0 mg/dL (34 µmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Thalidomide & Dexamethasone) (Type: EXPERIMENTAL): Thalidomide 50mg/day + Dexamethasone 40mg
- B (Dexamethasone and placebo) (Type: PLACEBO_COMPARATOR): Dexamethasone and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Resistance in Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12-18 years inclusive~* Typically developing and cognitively intact~Exclusion Criteria:~* Diabetes (≥126 mg dL-1 fasting glucose)~* Insulin treatment or sensitizing drugs~* Diagnosis of kidney, pulmonary, or heart disease~* Current smoking (defined as use of nicotine \>5 times in the past month)~* Pregnancy~* Neurological or developmental disorders (e.g., intellectual disability, autism)~* Significant head injury or medical conditions (e.g., concussion, encephalopathy, seizure disorder)~* Inability to undergo the MRI procedure~* Weight less than 94.5 lbs (42.9 kg) to adhere to safety guidelines regarding blood sampling and OGTT administration~* Tanner Stage \<3~* Any other circumstance deemed by the PI not addressed above

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Enrolled, eligible (Type: EXPERIMENTAL): Single arm for eligible subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent for participation in the study~2. Male and female age 18 or more at the time of signing the informed consent~3. SARS-CoV-2 infection confirmed by Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)~4. COVID-19 pneumonia with a typical radiological changes~5. PaO2/FIO2 ratio less than or equal to 300~6. COVID-19 Pneumonia in cytokine storm with elevated serum level of interleukin-6~Exclusion Criteria:~1. Use of fibrates other than fenofibrate or fenofibric acid~2. Known active infections or other clinical condition that contraindicate PCSK9 inhibitors~3. Known systemic hypersensitivity to PCSK9 inhibitors~4. Estimated glomerular filtration rate \<30 ml/min/1.73 m2~5. Absolute neutrophil count (ANC) less than 2000/mm3~6. A platelet count less than 50000/mm3~7. Creatine kinase (CK) greater than 3x upper limit of normal (ULN)~8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3x upper limit of normal (ULN)~9. Not expected to survive for more than 48 hours from screening~10. Unrelated co-morbidity with life expectancy \<3 months.~11. Pregnancy~12. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study~13. Patient being treated with other immunomodulators (except for glucocorticoids).~14. Patient included in any other interventional trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCSK9 inhibitor (evolocumab) (Type: EXPERIMENTAL): 140 mg of evolocumab as a single subcutaneous injection and standard of care accordance to the latest recommendations
- Usual Care (Type: PLACEBO_COMPARATOR): 1 ml of 0,9% saline solution as a single subcutaneous injection. Patients will be treated in accordance to the latest recommendations on caring for patients infected with SARS-CoV-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Receptor Levels and Smoking Cessation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Exclusion Criteria:~In addition to the exclusion criteria used for PNAT trial \[NCT01314001\], participants in this trial will be excluded if they meet the following criteria:~Imaging-Related Exclusion Criteria:~1. Weigh over 299 lbs.~2. Self-reported history of head trauma or brain (or CNS) tumor.~3. Self-reported history of claustrophobia (contraindicated for PET and MRI).~4. Cochlear implant or bilateral hearing aids.~5. Pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI.~6. History of gunshot wound (including BB guns).~7. Circumstances or conditions that may interfere with magnetic resonance imaging (MRI).~8. CO reading greater than 15ppm at the PET Scan Session (or at least a 50% reduction from the PNAT Intake Session).~9. BrAC reading greater than or equal to 0.01 at the PET Scan Session.~10. Positive urine drug screen for cocaine, phencyclidine, amphetamines, methamphetamines, tricyclic antidepressants, opiates, methadone, benzodiazepines, or barbiturates at the PNAT Intake Session or PET Scan Session.~11. Positive urine pregnancy (females only) screen at the PET Scan Session and/or MRI Scan Session.~12. Inability to give blood at the PET Scan Session (blood samples are required to analyze PET data).~13. Prior exposure to radioactive tracers in imaging studies or for medical reasons may be exclusionary.~General Exclusion Criteria:~1. Any medical condition, illness, disorder or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator or Co-investigators.~2. Inability to provide informed consent or complete the study procedures within 10 hours and/or correctly, as determined by the Principal Investigator or Co-investigators.~3. Any physical or visual impairment that would prevent completion of the cognitive tasks.~4. Participation (within the last 6 months) in other studies at our center involving similar cognitive testing procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Slow metabolizers (Type: None): Individuals with an NMR \<0.26 will be classified as slow metabolizers.
- Normal metabolizers (Type: None): Participants with an NMR \>= 0.26 will be classified as normal metabolizers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing coronary angiography+/-Percutaneous Coronary Intervention (PCI) for NSTE-ACS~2. Requirement for CIN prophylaxis as per Barts Heart Centre Criteria for CIN prophylaxis:~   eGFR\<60ml/min OR 2 of the following: diabetes, liver failure (cirrhosis), age \> 70yr, exposure to contrast in last 7 days, heart failure (or LVEF\<40%), concomitant renally active drugs (ACEi, ARB, NSAIDs, aminoglycosides, diuretics)~3. Aged \>18~4. Patients able and willing to give their written informed consent.~Exclusion Criteria:~1. ST segment myocardial infarction undergoing Primary PCI.~2. Patients with eGFR\<30ml/min or on renal replacement therapy~3. Subjects presenting with cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation~4. Current life-threatening condition other than vascular disease that may prevent a subject completing the study.~5. Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.~6. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).~7. Severe acute infection~8. Pregnancy~9. Breast-feeding mothers.~10. Any Inclusion Criteria not met

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Potassium Nitrate (Type: ACTIVE_COMPARATOR): Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
- Potassium Chloride (Type: PLACEBO_COMPARATOR): Potassium Chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~OA of the knee,K-L grade 2-3 in general good health is currently taking an NSAID or COX-2 inhibitor -~Exclusion Criteria:~pregant or nursing women grade 1 or 4 OA any significant medical condition that in the opinion of the physician might put the subject at risk in this study any form of arthropathy other than OA any condition that might confound the evaluation of the pain, stiffness or function of the target joint intra-articular cotticosteroid inkection in the target joint within 3 month of the screening visit concomitant use of other anti-inflammatory or anti arthritic medication or products(including OTC and herbal preparations) Low dose aspirin for cardio-protection is allowed concomitant use of coumadin or other anticoagulant or anti-platelet medication concomitant use of gastro-protectiv medications including, but not limited to, H2 blockers and proton pump inhibitors, including OTC and herbal products History of allergy to Flavonoids~-

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- flavocoxid (Type: EXPERIMENTAL): medical food
- naproxen (Type: ACTIVE_COMPARATOR): NSAID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Menthol Gel During Exercise With Heat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19-45 years of age~* cleared for physical activity via the 2022 physical activity readiness questionnaire (PARQ)~* no self-reported adverse reactions to menthol based gels~Exclusion Criteria:~* outside 19-45 years of age~* not cleared for physical activity via the 2022 physical activity readiness questionnaire (PARQ)~* self-report or signs of sensitivity to menthol gels~* pregnant~* breast feeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Menthol Gel first, then hypoallergenic gel (Type: EXPERIMENTAL): Participants randomized to receive menthol gel first then hypoallergenic gel after 7 day washout.~Gel is applied to the skin (arm and thigh). Participants walk on a treadmill for 30 minutes (3.5 mph at 5% grade) in 38°C and 60% relative humidity.
- Hypoallergenic Gel first, then menthol (Type: EXPERIMENTAL): Participants randomized to receive hypoallergenic gel first then menthol gel after 7 day washout.~Gel is applied to the skin (arm and thigh). Participants walk on a treadmill for 30 minutes (3.5 mph at 5% grade) in 38°C and 60% relative humidity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Men and women ≥18 years of age~* Patients with histologically or cytologically documented squamous cell nonsmall-cell lung cancer who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation for locally advanced disease~* Eastern Cooperative Oncology Group Performance Status of 0 or 1~* Disease progression or recurrence after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy~* Measurable disease by computed tomography scan/magnetic resonance imaging as per Response Evaluation Criteria in Solid Tumors, volume 1.1~Exclusion Criteria:~* Untreated central nervous system (CNS) metastases. Metastases have been treated and patients neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. In addition, patients must have stopped taking corticosteroids or be taking a stable or decreasing dose of ≤10 mg prednisone daily (or equivalent)~* Carcinomatous meningitis~* Active known or suspected autoimmune disease or interstitial lung disease~* Prior treatment on either arm of study CA209-017 or CA184-104~* Prior therapy with anti-Programmed death-1 (anti-PD-1), anti-Programmed cell death ligand 1 (anti-PD-L1), anti-Programmed cell death ligand 2 (anti-PD-L2), anti-CD137, or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways~* A condition requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days of first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab, 3 mg/kg (Type: EXPERIMENTAL): Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* both sexes;aged\>18 years;~* suffering from different types of malignancies(lung, breast,gastric,colon- rectum,pancreatic,ovarian,head and neck cancer)undergoing systemic chemotherapy,~* having signed Informed Consent prior to initiation of any study procedure.~EXCLUSION CRITERIA:~* adjuvant and neo-adjuvant chemotherapy;~* objectively confirmed venous or arterial thromboembolism in the last three months;~* antithrombotic treatment for other indications;~* life expectancy of less than 3 months;~* Performance Status\>2(ECOG);~* active bleeding or bleedings in the last four weeks requiring hospitalization,transfusion or surgical intervention;~* bleeding diathesis(prothrombin time\<70% or activated partial thromboplastin time ratio\>1.3),or platelet count\<50x10\^9/L;~* cerebrovascular hemorrhage in the last six months;~* known active gastric or duodenal ulcer;~* known cerebral metastasis;~* cerebral aneurysm;~* III-IV grade diabetic retinopathy;~* severe and uncontrolled hypertension(systolic blood pressure\>180 mmHg or diastolic blood pressure\>110 mmHg);~* chronic atrial fibrillation;~* acute endocarditis;~* acute pancreatitis;~* known hypersensitivity to unfractionated heparin or LMWH;~* previous occurrence of heparin-induced thrombocytopenia;~* renal impairment (dependent on dialysis or creatinine higher than 2.5mg%);~* liver insufficiency (alanine aminotransferase,aspartate aminotransferase,alkaline phosphatase levels\>3 times the upper limit of the normal ranges and/or total bilirubin \>3.0 mg/ml);~* pregnancy or childbearing potential without adequate contraception;~* treatment with other investigational drugs or patient inclusion in other clinical trials;~* patients who are unable to fulfill the study requirements in terms of visits/compliance to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- saline solution (Type: PLACEBO_COMPARATOR): Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
- nadroparin calcium (Type: EXPERIMENTAL): Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Development of a Mother/Child, Screen, Treat and Vaccinate Program in Manchay and Iquitos, Peru

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria (adult)~1. Non pregnant women 30-45 years of age in Manchay, and in Iquitos, with female children or grandchildren ages 10-13 who they are willing to enroll in the study to receive Gardasil vaccination.~2. No screening or knowledge of the results of a Pap Test in the last 5 years~3. No hysterectomy~4. No prior pelvic radiation.~5. Willing to sign consent form~Inclusion criteria (children)~1. Female children and grandchildren of a participating women ages 10-13 years~2. No acute illnesses (clinically evident according to vaccinating staff) - such as fever, nausea, vomiting, diarrhea~3. No previous vaccination with Gardasil~4. No reactions to previous dose in their vaccination series~5. No known yeast allergy~6. Willing to participate~Exclusion Criteria:~Exclusion criteria (adults)~Patients will be excluded in the study based on the following criteria:~1. Males~2. Women younger than 30 years old and older than 45 years old.~3. Women without female children or grandchildren age 10-13 or who are unwilling to enroll their 10-13 year old female children or grandchildren to receive Gardasil.~4. Pregnant women.~5. Patients with known history of hysterectomy or radiation for a pelvic cancer.~6. Refusal to participate~Exclusion criteria (Children)~1. Males~2. Girls younger than 10 years old, and older than 13 years.~3. acute illnesses (clinically evident according to vaccinating staff) - such as fever, nausea, vomiting, diarrhea~4. previous vaccination with Gardasil~5. reactions to a previous dose in their vaccination series~6. known yeast allergy~7. Refusal to participate

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients with essential hypertension~* Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.~* Patients who are eligible and able to participate in the study~Exclusion Criteria~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete